Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results

Jia, Zhongzhi; Paz‐Fumagalli, Ricardo; Frey, G; Sella, David M.; McKinney, J. Mark; Wang, Weiping

doi:10.1007/s00432-016-2291-4

Cited by 32 publications

(32 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were consistent with previous study, which show that radiotherapy did not provide a survival benefit for resection patients with positive resection margins and node negative ICC [22]. Recent studies also demonstrated the benefits of radiation in unresectable ICC [10], [23], [24].…”

Section: Discussionsupporting

confidence: 92%

Prognostic Factors and Treatment Strategies for Intrahepatic Cholangiocarcinoma from 2004 to 2013: Population-Based SEER Analysis

Liu

Zhong

Feng

et al. 2019

Translational Oncology

View full text Add to dashboard Cite

BACKGROUND: Seventy percent of intrahepatic cholangiocarcinoma (ICC) patients are inoperable. Treatment for unresectable patients is essential to improve poor survival. AIMS: We aimed to evaluate the prognostic factors for ICC patients, and investigate the potential treatment strategies for unresectable patients. METHODS: ICC patients were identified in SEER registry in 2004–2013. Univariate and multivariate Cox proportional hazard regression analysis were performed to evaluate the effect of treatment strategies. RESULTS: Of 2248 cases diagnosed in 2010–2013 and staged according to the American Joint Committee on Cancer (AJCC) 7th edition, 1706 (76.13%) did not receive cancer-directed surgery. This portion increased compared to those diagnosed between 2004 and 2009 and staged according to the AJCC 6th edition (72.87%). In addition, the percentage of stage 4 cases increased, while stage 3 cases decreased, because AJCC 7th staging system categorized both T4 and N1 patients into stage IV, which were previously categorized into stage III by AJCC 6th staging system. Patients with radiofrequency ablation (RFA) showed a poorer survival in 2004–2009 ( P = .0213), but an almost the same survival as patients with tumor resection in 2010–2013 ( P = .51), suggesting that RFA performed better in recent years. Lymphadenectomy showed protective effect for unresectable patients. Radiotherapy improved cancer-specific survival in non-surgery patients ( P < .0001).The proportion of stage IV patients increased tremendously from 37.4% in 2004–2009 to 58.7% in 2010–2013. Among 1319 stage IV patients (2010–2013), surgery at distant metastatic sites improved cancer-specific survival. CONCLUSIONS: For unresectable tumors, RFA, radiotherapy, lymphadenectomy, and surgery of distant metastases showed significant benefits to improve cancer-specific survival.

show abstract

Section: Discussionsupporting

confidence: 92%

Prognostic Factors and Treatment Strategies for Intrahepatic Cholangiocarcinoma from 2004 to 2013: Population-Based SEER Analysis

Liu

Zhong

Feng

et al. 2019

Translational Oncology

View full text Add to dashboard Cite

show abstract

“…In patients with cirrhosis (12 patients), liver toxicity appeared higher than in non-cirrhotic Median progression-free survival was 14 months [95%CI: [8][9][10][11][12][13][14][15][16][17], with a 12-months PFS rate of 55% and 24-months PFS rate of 30% ( Figure 3A). Median OS was 22 months [95% CI: 14-52], with a 12-months OS rate of 75% and 24-months OS rate of 45% ( Figure 3B).…”

Section: Treatment Received and Safetymentioning

confidence: 99%

Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Radiolabeled microspheres are administrated via the hepatic arteries, delivering a local radiation dose when reaching the tumor vasculature. Multiple single-center series reported results of RE in BTC [6][7][8][9][10][11][12][13][14][15][16][17], however the largest published to date included only 46 patients [11]. There is still considerable uncertainty about potential prognostic factors and about the potential preferred population in which this treatment should be applied [15,18].…”

Section: Introductionmentioning

confidence: 99%

Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience

Bourien

Palard

Rolland

et al. 2018

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose: Radioembolization (RE) is a promising treatment option for biliary tract cancers (BTC). We report here the largest series to date using this treatment modality. Methods: We retrospectively studied data from 64 patients treated outside prospective clinical trial at our institution. We studied baseline characteristics as potential prognostic factors. We studied dose delivered to the tumor as predictive factors of outcomes in patients not receiving concomitant chemotherapy. Results: The Progression-Free Survival and Overall Survival (OS) survival were 7.6 months [95% Confidence Interval (

show abstract

Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results

Abstract: Resin-based Y radioembolization can provide palliative control of unresectable and failed first-line chemotherapy ICC in a salvage setting with acceptable side effects.

Cited by 32 publications

References 31 publications

Prognostic Factors and Treatment Strategies for Intrahepatic Cholangiocarcinoma from 2004 to 2013: Population-Based SEER Analysis

Prognostic Factors and Treatment Strategies for Intrahepatic Cholangiocarcinoma from 2004 to 2013: Population-Based SEER Analysis

Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma

Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience

Contact Info

Product

Resources

About